A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate

Brenda Wittman, John Horan, Joanna Baxter, John Goldberg, Raymond Felgar, Erin Baylor, Bean Cromwell, Nicholas Cross, John M. Bennett

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Atypical chronic myelogenous leukemia (aCML) is a myelodysplastic/ myeloproliferative disorder that usually occurs in older adults. Here we report a pediatric patient with aCML and a t(5;12)(q33;p13) with a corresponding fusion gene ETV6-PDGFRB. Because the PDGFRB tyrosine kinase is one of the known targets of tyrosine kinase inhibitors, this patient achieved cytogenetic and molecular remission with treatment with imatinib mesylate (formerly STI571; now Gleevec in the United States and Glivec in Europe). This case illustrates one of many myelodysplastic/myeloproliferative disorders that can be treated with this particular tyrosine kinase inhibitor.

Original languageEnglish (US)
Pages (from-to)65-69
Number of pages5
JournalLeukemia Research
Volume28
Issue numberSUPPL. 1
DOIs
StatePublished - May 2004

Keywords

  • Atypical CML
  • ETV6-PDGFRB fusion gene
  • Imatinib mesylate
  • t(5;12)

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate'. Together they form a unique fingerprint.

Cite this